ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2958

Validation of Flare Criteria for Children and Adolescents with Systemic Lupus Erythematosus

Hermine I. Brunner1, Michael J. Holland2, Michael W. Beresford3, Nicolino Ruperto4, Stacy P. Ardoin5, Simone Appenzeller6, Clovis A Silva7, Glaucia V. Novak7, Daniela M. Lourenço8, Francisco Flores9, Beatrice Goilav10, Scott E. Wenderfer11, Deborah M. Levy12, Angelo Ravelli13, Raju Khubchandani14, Tadej Avcin15, Marisa S. Klein-Gitelman16, Brian M. Feldman17 and Jun Ying18, 1Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 2Pediatric Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 3On Behalf of the UK JSLE Study Group, Liverpool, United Kingdom, 4Istituto Giannina Gaslini, Genoa, Italy, 5Pediatric & Adult Rheumatology, The Ohio State University Wexner Medical Center, Columbus, OH, 6Pediatric Rheumatology Unit, State University of Campinas, Campinas, Brazil, 7Pediatric Rheumatology Unit, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, 8Pediatric Rheumatology Unit, Faculdade de Medicina da Universidade de São Paulo, Sao Paulo, Brazil, 9Nephrology and Hypertension, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 10Albert Einstein College of Medicine/Montefiore Medical Center, New York, NY, 11Pediatrics-Renal, Baylor College of Medicine, Texas Children's Hospital, Houston, TX, 12Division of Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada, 13University of Genova, IRCCS Istituto Giannina Gaslini, Genova, Italy, 14Department of Paediatrics, Jaslok Hospital and Research Center, Mumbai, India, 15Istituto Giannina Gaslini - Pediatria II, Reumatologia - PRINTO, Genoa, Italy, 16Division of Pediatric Rheumatology/PDD PTD, Lurie Children's Hospital of Chicago/Northwestern University, Chicago, IL, 17Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada, 18Center for Biostatistical Services, University of Cincinnati College of Medicine, Cincinnati, OH

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: Disease Activity, measure and systemic lupus erythematosus (SLE)

  • Tweet
  • Email
  • Print
Session Information

Date: Wednesday, November 8, 2017

Title: Pediatric Rheumatology – Clinical and Therapeutic Aspects III: Lupus, Dermatomyositis, and Scleroderma

Session Type: ACR Concurrent Abstract Session

Session Time: 11:00AM-12:30PM

Background/Purpose: Childhood-onset systemic lupus erythematosus (cSLE) is characterized by changing disease activity: episodes of improvement are often followed by episodes of worsening, i.e. flares. Considering changes of previously defined core response variables (proteinuria [mostly from protein creatinine ratio, PCR], disease activity (SLEDAI, BILAG), physician global assessment of cSLE activity), and ESR, preliminary flare algorithms have been derived by Classification Tree Analysis (CART) and multinomial logistic regression (MLR), respectively. International consensus yielded 4 preferred criteria for detection of cSLE flares, based on initial validation in 2010-11. These algorithms yield flare-scores, with higher scores reflecting worse flares. Our objective was to validate the preliminary cSLE flare algorithms, and delineate flare scores that reflect mild/moderate/major flares.

Methods: A total of 1,860 Patient Profiles (PPs) providing relevant data at baseline and follow-up were generated from existing international prospective cSLE cohorts, with systematic imputation of missing algorithm variables. Pediatric rheumatologists (PP-raters) were asked to judge disease courses between baseline and follow-up as:  improved, no change, mild flare, moderate flare, or major flare. Based on majority opinion of PP-raters, each PP was assigned a true disease course, against which the flare algorithms were tested for accuracy. Using two complementary approaches (distribution-weighted, MLR-based) potential threshold flare-scores for flare severity (mild, moderate, major) were derived and tested for accuracy via area under the receiver operating characteristic curve (AUC).  Analyses were reviewed by an expert panel that used nominal group technique to achieve consensus (≥75% agreement).

Results:   Among 503 invited, feedback from 274 PP-raters (53% response rate) was available for analysis. Based on PP-rater feedback, true disease courses were as follows: 540 no change or improved and 510/483/325 PPs as mild flare/ moderate flare/ major flare. There was consensus to use MLR estimates for all flare thresholds. As shown (Table 1), CART-based models, though maintaining very good to excellent accuracy (AUCs for mild/moderate/major flares all >70%), were less suited to discriminate mild and moderate flares. Algorithms from MLR maintained outstanding accuracies (all AUC > 90.79%) and had sensitivities/specificities for mild/moderate/major flares all >82%/>82% in the 2017 validation analyses. This was true for both BILAG and SLEDAI-based algorithms (see Table 1).

Conclusion:  The provisional criteria for flare of global disease of cSLE have outstanding accuracy in identifying flare in cSLE with different degrees of severity. Based on our results and consensus, the BILAG and the SLEDAI-based algorithm from MLR are equally acceptable to measure flares in cSLE.


Table 1: Comparison of the Performance of the Preliminary Flare Algorithm in the Development and Validation Dataset        

Method

Preliminary Flare Algorithms*

Flare severity

Threshold scores from logistic regression

Area under ROC­ curve

2010 data

2017 data

Logistic regression

0.5 x SLEDAI + 0.45 X PCR + 0.5 X MD-global+ 0.02 x ESR

Major

6.4

95.12%

93.11%

Less than or equal to Moderate

3.0

85.14%

93.94%

Less than or equal to Mild

0.6

85.99%

93.11%

0.4 x BILAG  + 0.65 X PCR + 0.5 X MD-global + 0.02 x ESR

Major

7.4

93.10%

90.79%

Less than or equal to Moderate

3.7

84.92%

92.04%

Less than or equal to Mild

2.2

84.81%

93.06%

Classification tree analysis (CART)

S4 if 3 less than or equal to SLEDAI;
S3 if 0.7 less than or equal to PCR;
S2 if 2 less than or equal to MD-global;
S1 Other

Major

4

85.14%

76.21%

Less than or equal to Moderate

3

79.52%

80.17%

Less than or equal to Mild

3

83.86%

89.01%

S4 if 2 less than or equal to BILAG;
S3 if 0.7 less than or equal to PCR;
S2 if 2 less than or equal to MD-global;
S1 Other

Major

4

85.92%

70.66%

Less than or equal to Moderate

3

79.52%

74.59%

Less than or equal to Mild

3

82.24%

84.12%

* In all algorithms changes (worsening) of the variables are considered, e.g. change in SLEDAI, change in proteinuria, etc; MD-global: Physician global assessment of disease measured on a visual analog scale (range: 0-10; 0= inactive disease), PCR proteinuria estimated from 24-hr timed collection or random urine sample; ­  Receiver operating characteristic;   A=12; B=8, C=1,D/E = 0

(1) Details about algorithm development are provided in Brunner, H. I., R. Mina, "Preliminary criteria for global flares in childhood-onset systemic lupus erythematosus." Arthritis Care Res (Hoboken) 63(9): 1213-1223.


Disclosure: H. I. Brunner, None; M. J. Holland, None; M. W. Beresford, None; N. Ruperto, BMS, Hoffman-La Roche, Janssen, Novartis, Pfizer and Sobi, 2,Abbvie, Ablynx, AstraZeneca, Baxalta Biosimilars, Biogen Idec, Boehringer, Bristol Myers Squibb, Eli-Lilly, EMD Serono, Gilead Sciences, Janssen, Medimmune, Novartis, Pfizer, Rpharm, Roche, Sanofi., 5,Abbvie, Ablynx, AstraZeneca, Baxalta Biosimilars, Biogen Idec, Boehringer, Bristol Myers Squibb, Eli-Lilly, EMD Serono, Gilead Sciences, Janssen, Medimmune, Novartis, Pfizer, Rpharm, Roche, Sanofi., 8; S. P. Ardoin, not applicable, 9; S. Appenzeller, None; C. A. Silva, Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP #2014/14806-0 and 2015/03756-4 to CAS), Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq 303422/2015-7 - 1A to CAS), 2; G. V. Novak, None; D. M. Lourenço, None; F. Flores, None; B. Goilav, None; S. E. Wenderfer, None; D. M. Levy, None; A. Ravelli, None; R. Khubchandani, None; T. Avcin, None; M. S. Klein-Gitelman, Janssen Pharmaceutica Product, L.P., 2,Pfizer Inc, 2,UCB biosciences, 2,Abbvie, 2,Lupus Foundation of America, 2,NIH/LFA/Cure JM/Arthritis Foundation, 2,Up to Date, 7; B. M. Feldman, None; J. Ying, None.

To cite this abstract in AMA style:

Brunner HI, Holland MJ, Beresford MW, Ruperto N, Ardoin SP, Appenzeller S, Silva CA, Novak GV, Lourenço DM, Flores F, Goilav B, Wenderfer SE, Levy DM, Ravelli A, Khubchandani R, Avcin T, Klein-Gitelman MS, Feldman BM, Ying J. Validation of Flare Criteria for Children and Adolescents with Systemic Lupus Erythematosus [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/validation-of-flare-criteria-for-children-and-adolescents-with-systemic-lupus-erythematosus/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/validation-of-flare-criteria-for-children-and-adolescents-with-systemic-lupus-erythematosus/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology